Q3-FY26 · Keshav Bada
Whatever heavy lifting was required for the company on the investment side, we have largely completed in last many years and the focus now is on execution, scaling and getting maximum ROC from all our investment.
SHILPAMED / language trends
Read confidence between the lines.
Shilpa Medicare · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Alpesh Dalal
9 month PAT is nearly double of full year PAT of FY25 reflecting the acceleration that we are witnessing in our growth and we have also incurred a capex of about 87 crores during the third quarter.
Q3-FY26 · Keshav Bada
Albumin by itself is a shortage product always. It has lot of complexities on supply chain. Bringing a recombinant version purer version will always have advantage.